InkVivo

Executive Summary

InkVivo Technologies, a Swiss private company founded in 2020 and based in Lausanne, is developing a proprietary polymer platform for next-generation drug delivery. The platform enables controlled, localized, and sustained release of a broad range of active ingredients—from small molecules to biologics—via oral and injectable routes. By improving therapeutic outcomes and patient quality of life, InkVivo addresses key limitations in current drug delivery, such as frequent dosing, systemic side effects, and poor bioavailability. The company operates at the intersection of materials science and pharmaceutics, aiming to increase the efficacy of existing drugs and enable new modalities. While still in early stages (no disclosed funding or stage), InkVivo’s technology could have applications across oncology, chronic diseases, and biologics delivery. The company is part of the vibrant Swiss biotech ecosystem, known for innovation in precision medicine and drug delivery. However, without disclosed funding rounds or partnerships, the company remains pre-revenue and unvalidated by clinical data. The management team and specific preclinical results are not publicly available, limiting near-term visibility. Nonetheless, the platform’s versatility and the growing demand for advanced delivery systems position InkVivo as a potential candidate for future investment or licensing partnerships, provided it can demonstrate in vivo proof-of-concept and scalability.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Round40% success
• 2027Partnership with Large Pharma for Platform Licensing25% success
• Q3 2026Publication of Preclinical In Vivo Data50% success